Cargando…

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

BACKGROUND: Tenofovirdisoproxilfumarate (TDF) is a nucleotide analogue widely recommended in international HIV treatment guidelines. The association of TDF and renal dysfunction has remained an area of interest. FINDINGS: We conducted a retrospective review of all patients on TDF from July 2007 to D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chua, Arlene C, Llorin, Ryan M, Lai, Kelvin, Cavailler, Philippe, Law, Hwa Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443451/ https://www.ncbi.nlm.nih.gov/pubmed/22703627 http://dx.doi.org/10.1186/1742-6405-9-19

Ejemplares similares

Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
por: Bygrave, Helen, et al.
Publicado: (2011)

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
por: Aurpibul, Linda, et al.
Publicado: (2019)

Delayed onset renal failure in a patient on tenofovir based antiretroviral regimen
por: Krishna, M. Murali, et al.
Publicado: (2014)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Opt-out of Voluntary HIV Testing: A Singapore Hospital's Experience
por: Chua, Arlene C., et al.
Publicado: (2012)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function
por: Guillemi, Silvia A, et al.
Publicado: (2016)

107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects
por: Darnell, Julia, et al.
Publicado: (2020)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide
por: Hung, Anna, et al.
Publicado: (2020)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens
por: Nkhoma, Ella T., et al.
Publicado: (2016)

Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India
por: Kumarasamy, Nagalingeswaran, et al.
Publicado: (2018)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

Low Incidence of Renal Dysfunction among HIV-Infected Patients on a Tenofovir-Based First Line Antiretroviral Treatment Regimen in Myanmar
por: Kyaw, Nang Thu Thu, et al.
Publicado: (2015)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
por: Emond, Bruno, et al.
Publicado: (2022)

Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV
por: McLaughlin, Milena M, et al.
Publicado: (2018)

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment
por: Lapadula, Giuseppe, et al.
Publicado: (2016)

Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya
por: Karoney, Mercy Jelagat, et al.
Publicado: (2022)

Lack of utility of phosphate serum monitoring in HIV-infected patients on a tenofovir-based antiretroviral regimen
por: Wikman, P, et al.
Publicado: (2010)

Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial
por: Decloedt, Eric H., et al.
Publicado: (2017)

Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam
por: Hoang, Cuong Q, et al.
Publicado: (2020)

Safety of Tenofovir Disoproxil Fumarate–Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis
por: Nachega, Jean B., et al.
Publicado: (2017)

Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
por: Horizon, Arash A, et al.
Publicado: (2011)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
por: Yilma, Daniel, et al.
Publicado: (2020)

The 10 year safety and efficacy of tenofovir disoproxil fumarate (TDF)-containing once-daily highly active antiretroviral therapy (HAART)
por: Cassetti, I, et al.
Publicado: (2010)

Viral Blips Were Infrequent in HIV-1-Infected Virologically-Suppressed Adults Treated with Tenofovir Alafenamide or Tenofovir DF Rilpivirine-Containing Regimens
por: Wohl, David A, et al.
Publicado: (2017)

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial
por: Thurman, Andrea R., et al.
Publicado: (2021)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults
por: Agbaji, Oche O., et al.
Publicado: (2019)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

Simultaneous Spectrophotometric Estimation of Tenofovir Disoproxil Fumarate and Lamivudine in Three Component Tablet Formulation Containing Efavirenz
por: Sharma, R., et al.
Publicado: (2010)

1614. Efficacy and Safety of Adjusted Renal Dosing of Tenofovir DF Versus Abacavir Switching in HIV Patients with Decreased Glomerular Filtration Rate After Receiving Tenofovir DF-Based Regimen
por: Yamasmith, Eakkawit, et al.
Publicado: (2023)

Impact of medication safety initiatives on patient safety culture in a community pharmacy in Singapore
por: Miao, Jing, et al.
Publicado: (2022)

Patients’ Willingness to Take Multiple-Tablet Antiretroviral Therapy Regimens for Treatment of HIV
por: Engelhard, Esther A. N., et al.
Publicado: (2016)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
por: Gupta, Samir K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_do0un7kbai11037m3odv12kpsh